|
Y. enterocolititica Subunit V Antigen Protein Vaccine |
Yersinia enterocolitica aroA mutant vaccine |
Yersinia enterocolitica htrA mutant vaccine |
Yersinia enterocolitica ompR mutant vaccine |
Yersinia enterocolitica sodA mutant vaccine |
| Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
Vaccine Information |
- Vaccine Ontology ID: VO_0011503
- Type: Subunit vaccine
- Status: Research
- LcrV
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: Subcutaneous injection
|
- Vaccine Ontology ID: VO_0002935
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- aroA
gene engineering:
- Type: Gene mutation
- Description: This aroA mutant is from Yersinia enterocolitica (Bowe et al., 1989).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
- Vaccine Ontology ID: VO_0002936
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- htrA
gene engineering:
- Type: Gene mutation
- Description: This htrA mutant is from Yersinia enterocolitica (Li et al., 1996).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
- Vaccine Ontology ID: VO_0002937
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- ompR
gene engineering:
- Type: Gene mutation
- Description: This ompR mutant is from Yersinia enterocolitica (Dorrell et al., 1998).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
- Vaccine Ontology ID: VO_0002938
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- sodA
gene engineering:
- Type: Gene mutation
- Description: This sodA mutant is from Yersinia enterocolitica (Igwe et al., 1999).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
| Host Response |
Host Response |
Host Response |
Host Response |
Host Response |
|
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: Mice were injected subcutaneously (s.c.) with 30 lg rVagHis in CFA and boostered with 30 lg rVagHis in ICFA four weeks later. Control mice were treated similarily with CFA or ICFA, but lacking rVagHis (Schmidt et al., 1999).
- Challenge Protocol: Mice were challenged intraperitoneally (i.p.) with 0.5 ml bacterial suspension containing either 3x10^3 cells of Y. enterocolitica 0:8 strain NCTC10938 or 4x10^4 cells of Y. pseudotuberculosis strain YPlll/pIB102. Survival of mice was monitored over 2 months (Schmidt et al., 1999).
- Efficacy: Mice actively immunized using a recombinant V antigen (rVagHis, encoded by lcrV gene) of Y. enterocolitica were completely protected against challenge with both, Y. enterocolitica 0:8 and Y. pseudotuberculosis serotype III (Schmidt et al., 1999).
|
Mouse Response
- Persistence: An aroA mutant is highly attenuated in mice (Bowe et al., 1989).
- Efficacy: After 3 doses, an aroA mutant induces significant protection in mice from challenge with wild type Y. enterocolitica (Bowe et al., 1989).
|
Mouse Response
- Persistence: An htrA mutant is attenuated in mice (Li et al., 1996).
- Efficacy: An htrA mutant provides partial protection in mice from challenge with wild type Y. enterocolitica (Li et al., 1996).
|
Mouse Response
- Persistence: An ompR mutant is attenuated in mice (Dorrell et al., 1998).
- Efficacy: An ompR mutant provided partial protection in mice from challenge with wild type Y. enterocolitica (Dorrell et al., 1998).
|
Mouse Response
- Persistence: A sodA mutant is attenuated in mice (Igwe et al., 1999).
- Efficacy: A single dose of a sodA mutant provided protection in mice from challenge with wild type Y. enterocolitica (Igwe et al., 1999).
- Host Ifng (Interferon gamma) response
- Description: Restimulated T cells from mice immunized with the mutant strains produced significant quantities of IFN-γ by day 8 after oral immunization compared to the control group of nonrestimulated T cells. However, the amounts of IFN-γ produced by T cells from mice immunized with the mutant strains were lower than those of mice immunized with the wild-type Y. enterocolitica strain (Igwe et al., 1999).
- Detailed Gene Information: Click Here.
- Host IgG response
- Description: Mice immunized with a sodA mutant elicited high titers of serum IgG antibodies. On day 23, WA-314 sodA elicited a 17-fold-higher titer of Yersinia-specific serum IgG antibody than WA irp1 (an irp1 mutant). Mice immunized with WA-314 sodA elicited a 10-fold-higher titer of serum IgG antibody than those given WA(pYVO8-A-2) (a YadA mutant) 90 days after the immunization. IgG levels from days 7 to 90 post-immunization were significantly greater than control serum obtained pre-immunization (Igwe et al., 1999).
- Detailed Gene Information: Click Here.
|
| References |
References |
References |
References |
References |
Schmidt et al., 1999: Schmidt A, Schaffelhofer S, Müller K, Röllinghoff M, Beuscher HU. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity. Microbial pathogenesis. 1999; 26(4); 221-233. [PubMed: 10089162].
|
Bowe et al., 1989: Bowe F, O'Gaora P, Maskell D, Cafferkey M, Dougan G. Virulence, persistence, and immunogenicity of Yersinia enterocolitica O:8 aroA mutants. Infection and immunity. 1989; 57(10); 3234-3236. [PubMed: 2777382].
|
Li et al., 1996: Li SR, Dorrell N, Everest PH, Dougan G, Wren BW. Construction and characterization of a Yersinia enterocolitica O:8 high-temperature requirement (htrA) isogenic mutant. Infection and immunity. 1996; 64(6); 2088-2094. [PubMed: 8675311].
|
Dorrell et al., 1998: Dorrell N, Li SR, Everest PH, Dougan G, Wren BW. Construction and characterisation of a Yersinia enterocolitica O:8 ompR mutant. FEMS microbiology letters. 1998; 165(1); 145-151. [PubMed: 9711851].
|
Igwe et al., 1999: Igwe EI, Rüssmann H, Roggenkamp A, Noll A, Autenrieth IB, Heesemann J. Rational live oral carrier vaccine design by mutating virulence-associated genes of Yersinia enterocolitica. Infection and immunity. 1999; 67(10); 5500-5507. [PubMed: 10496939].
|
